CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Black Diamond Therapeutics, Inc. (BDTX) on Tuesday reported a loss of $15.6 million in its third quarter. The Cambridge, Massachusetts-based ...
Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, ...
TD Cowen analyst Marc Frahm has maintained their bullish stance on BDTX stock, giving a Buy rating today. Marc Frahm’s rating is based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback